Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris.

Wiederhold NP, Lockhart SR, Najvar LK, Berkow EL, Jaramillo R, Olivo M, Garvey EP, Yates CM, Schotzinger RJ, Catano G, Patterson TF.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02233-18. doi: 10.1128/AAC.02233-18. Print 2019 Mar.

PMID:
30530603
2.

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.

Wiederhold NP, Xu X, Wang A, Najvar LK, Garvey EP, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Brand SR, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01315-18. doi: 10.1128/AAC.01315-18. Print 2018 Nov.

3.

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.

Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01071-18. doi: 10.1128/AAC.01071-18. Print 2018 Sep.

4.

The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis.

Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Birch M, Law D, Rex JH, Catano G, Patterson TF.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00999-18. doi: 10.1128/AAC.00999-18. Print 2018 Sep.

5.

The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.

Wiederhold NP, Shubitz LF, Najvar LK, Jaramillo R, Olivo M, Catano G, Trinh HT, Yates CM, Schotzinger RJ, Garvey EP, Patterson TF.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02258-17. doi: 10.1128/AAC.02258-17. Print 2018 Apr.

6.

Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.

Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Pizzini J, Catano G, Patterson TF.

J Antimicrob Chemother. 2018 Feb 1;73(2):448-451. doi: 10.1093/jac/dkx422.

7.

Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Maincent JP, Najvar LK, Kirkpatrick WR, Huang S, Patterson TF, Wiederhold NP, Peters JI, Williams RO 3rd.

Drug Dev Ind Pharm. 2017 Feb;43(2):264-274. doi: 10.1080/03639045.2016.1236811. Epub 2016 Oct 5.

8.

Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.

Kadosh D, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Wiederhold NP, Patterson TF.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6703-6708. doi: 10.1128/AAC.01144-16. Print 2016 Nov.

9.

Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5600-3. doi: 10.1128/AAC.00229-16. Print 2016 Sep.

10.

Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model.

White PL, Wiederhold NP, Loeffler J, Najvar LK, Melchers W, Herrera M, Bretagne S, Wickes B, Kirkpatrick WR, Barnes RA, Donnelly JP, Patterson TF.

J Clin Microbiol. 2016 Apr;54(4):960-6. doi: 10.1128/JCM.03233-15. Epub 2016 Jan 20.

11.

The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Fukuda Y, Mitsuyama J, Patterson TF.

J Antimicrob Chemother. 2016 Mar;71(3):692-5. doi: 10.1093/jac/dkv398. Epub 2015 Nov 29.

12.

Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Matsumoto S, Bocanegra RA, Herrera ML, Wickes BL, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2015 May;59(5):2875-81. doi: 10.1128/AAC.04857-14. Epub 2015 Mar 9.

13.

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF.

Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14. Epub 2014 Dec 1.

14.

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF.

Antimicrob Agents Chemother. 2015 Jan;59(1):690-2. doi: 10.1128/AAC.03944-14. Epub 2014 Oct 20.

15.

Prolyl endopeptidase activity in bronchoalveolar lavage fluid: a novel diagnostic biomarker in a guinea pig model of invasive pulmonary aspergillosis.

Jambunathan K, Watson DS, Najvar LK, Wiederhold NP, Kirkpatrick WR, Patterson TF, Askew DS, Kodukula K, Galande AK.

Med Mycol. 2013 Aug;51(6):592-602. doi: 10.3109/13693786.2012.761360. Epub 2013 Jan 28.

PMID:
23356446
16.

Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF, Thornton CR.

J Clin Microbiol. 2013 Feb;51(2):459-65. doi: 10.1128/JCM.02142-12. Epub 2012 Nov 21.

17.

Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Sorrell TC, Patterson TF.

Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.

18.

A murine model of Cryptococcus gattii meningoencephalitis.

Thompson GR 3rd, Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Graybill JR, Patterson TF.

J Antimicrob Chemother. 2012 Jun;67(6):1432-8. doi: 10.1093/jac/dks060. Epub 2012 Feb 29.

19.

Assessment of Aspergillus fumigatus in guinea pig bronchoalveolar lavages and pulmonary tissue by culture and realtime polymerase chain reaction studies.

Hooper DG, Bolton VE, Sutton JS, Guilford FT, Straus DC, Najvar LK, Wiederhold NP, Kirkpatrick WR, Patterson TF.

Int J Mol Sci. 2012;13(1):726-36. doi: 10.3390/ijms13010726. Epub 2012 Jan 11.

20.

Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.

Kirkpatrick WR, Najvar LK, Vallor AC, Wiederhold NP, Bocanegra R, Pfeiffer J, Perkins K, Kugler AR, Sweeney TD, Patterson TF.

J Antimicrob Chemother. 2012 Apr;67(4):970-6. doi: 10.1093/jac/dkr567. Epub 2012 Jan 11.

PMID:
22240402
21.

Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection.

Lengerova M, Kocmanova I, Racil Z, Hrncirova K, Pospisilova S, Mayer J, Najvar LK, Wiederhold NP, Kirkpatrick WR, Patterson TF.

J Clin Microbiol. 2012 Mar;50(3):602-8. doi: 10.1128/JCM.05356-11. Epub 2011 Dec 21.

22.

Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF.

Clin Microbiol Infect. 2012 Feb;18(2):E20-3. doi: 10.1111/j.1469-0691.2011.03712.x. Epub 2011 Nov 30.

23.

Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2011 Jul;55(7):3254-60. doi: 10.1128/AAC.01750-10. Epub 2011 Apr 18.

24.

Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.

Wiederhold NP, Najvar LK, Bocanegra R, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2010 Mar;54(3):1055-9. doi: 10.1128/AAC.01445-09. Epub 2010 Jan 11.

25.

Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis.

Wiederhold NP, Thornton CR, Najvar LK, Kirkpatrick WR, Bocanegra R, Patterson TF.

Clin Vaccine Immunol. 2009 Dec;16(12):1844-6. doi: 10.1128/CVI.00268-09. Epub 2009 Sep 30.

26.

Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.

Tolman JA, Wiederhold NP, McConville JT, Najvar LK, Bocanegra R, Peters JI, Coalson JJ, Graybill JR, Patterson TF, Williams RO 3rd.

Antimicrob Agents Chemother. 2009 Jun;53(6):2613-5. doi: 10.1128/AAC.01657-08. Epub 2009 Mar 16.

27.

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.

Brzankalski GE, Najvar LK, Wiederhold NP, Bocanegra R, Fothergill AW, Rinaldi MG, Pattterson TF, Graybill JR.

J Antimicrob Chemother. 2008 Nov;62(5):1094-100. doi: 10.1093/jac/dkn304. Epub 2008 Jul 25.

28.

Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Vallor AC, Kirkpatrick WR, Najvar LK, Bocanegra R, Kinney MC, Fothergill AW, Herrera ML, Wickes BL, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2593-8. doi: 10.1128/AAC.00276-08. Epub 2008 May 12.

29.

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice.

Najvar LK, Bocanegra R, Wiederhold NP, Lambros C, Najarian N, Patterson TF, Graybill JR.

Clin Microbiol Infect. 2008 Jun;14(6):595-600. doi: 10.1111/j.1469-0691.2008.01994.x. Epub 2008 Apr 5.

30.

Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Vallor AC, Kirkpatrick WR, Bocanegra R, Molina D, Olivo M, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Mar;52(3):1176-8. Epub 2007 Dec 26.

31.

Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model.

González GM, González G, Najvar LK, Graybill JR.

J Antimicrob Chemother. 2007 Dec;60(6):1341-6. Epub 2007 Oct 12.

PMID:
17934204
32.

New guinea pig model of Cryptococcal meningitis.

Kirkpatrick WR, Najvar LK, Bocanegra R, Patterson TF, Graybill JR.

Antimicrob Agents Chemother. 2007 Aug;51(8):3011-3. Epub 2007 Jun 11.

33.

Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Coalson JJ, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO 3rd.

J Infect. 2007 Jul;55(1):68-74. Epub 2007 Mar 13.

PMID:
17360039
34.

In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.

Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR.

Antimicrob Agents Chemother. 2007 May;51(5):1616-20. Epub 2007 Feb 16.

35.

Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Sheppard DC, Graybill JR, Najvar LK, Chiang LY, Doedt T, Kirkpatrick WR, Bocanegra R, Vallor AC, Patterson TF, Filler SG.

Antimicrob Agents Chemother. 2006 Oct;50(10):3501-3.

36.

In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP.

Antimicrob Agents Chemother. 2006 Nov;50(11):3926-8. Epub 2006 Aug 28.

37.

Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus.

Steinbach WJ, Cramer RA Jr, Perfect BZ, Asfaw YG, Sauer TC, Najvar LK, Kirkpatrick WR, Patterson TF, Benjamin DK Jr, Heitman J, Perfect JR.

Eukaryot Cell. 2006 Jul;5(7):1091-103.

38.

Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production.

Cramer RA Jr, Gamcsik MP, Brooking RM, Najvar LK, Kirkpatrick WR, Patterson TF, Balibar CJ, Graybill JR, Perfect JR, Abraham SN, Steinbach WJ.

Eukaryot Cell. 2006 Jun;5(6):972-80.

39.

In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, Wiederhold NP, Frei BL, Graybill JR, Bocanegra R, Overhoff KA, Sinswat P, Johnston KP, Williams RO 3rd.

Antimicrob Agents Chemother. 2006 Apr;50(4):1552-4.

40.

Topical voriconazole as a novel treatment for fungal keratitis.

Sponsel W, Chen N, Dang D, Paris G, Graybill J, Najvar LK, Zhou L, Lam KW, Glickman R, Scribbick F.

Antimicrob Agents Chemother. 2006 Jan;50(1):262-8.

41.

Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.

Bocanegra R, Najvar LK, Hernandez S, McCarthy DI, Graybill JR.

Antimicrob Agents Chemother. 2005 Dec;49(12):5139-41.

42.

Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits.

Harrison JM, Glickman RD, Ballentine CS, Trigo Y, Pena MA, Kurian P, Najvar LK, Kumar N, Patel AH, Sponsel WE, Graybill JR, Lloyd WC 3rd, Miller MM, Paris G, Trujillo F, Miller A, Melendez R.

Doc Ophthalmol. 2005 Jan;110(1):37-55.

PMID:
16249956
43.

Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana.

Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR.

Antimicrob Agents Chemother. 2005 May;49(5):1701-7.

44.

Antifungal therapy of murine Aspergillus terreus infection.

Graybill JR, Hernandez S, Bocanegra R, Najvar LK.

Antimicrob Agents Chemother. 2004 Oct;48(10):3715-9.

45.

Alternatives to amphotericin B for Candida rugosa infection.

Hernandez S, Gonzalez GM, McCarthy DI, Colombo AL, Najvar LK, Bocanegera R, Graybill JR.

J Antimicrob Chemother. 2004 Aug;54(2):477-80. Epub 2004 Jun 23.

PMID:
15215225
46.

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.

Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jun;48(6):2288-91.

47.

Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.

González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi MG, Graybill JR.

Antimicrob Agents Chemother. 2004 Jun;48(6):2140-3.

48.
49.

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

Najvar LK, Cacciapuoti A, Hernandez S, Halpern J, Bocanegra R, Gurnani M, Menzel F, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2004 Mar;48(3):758-64.

50.

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.

Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK.

J Antimicrob Chemother. 2003 Oct;52(4):656-62. Epub 2003 Sep 12.

PMID:
12972452

Supplemental Content

Loading ...
Support Center